AKYA - Akoya Biosciences Inc
IEX Last Trade
2.545
-0.095 -3.733%
Share volume: 149,945
Last Updated: Fri 30 Aug 2024 09:59:55 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.87%
PREVIOUS CLOSE
CHG
CHG%
$2.64
-0.10
-3.60%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-09 | 2022-11-08 | 2023-03-07 | 2023-05-09 | 2023-08-08 | 2023-11-09 | 2024-03-05 | 2024-05-14 | |
| Assets | |||||||||
| Total Assets | 184.263 M | 176.457 M | 176.031 M | 154.297 M | 188.879 M | 177.244 M | 180.369 M | 154.750 M | |
| Current Assets | 119.894 M | 111.744 M | 112.197 M | 91.674 M | 126.170 M | 116.948 M | 121.790 M | 101.829 M | |
| Inventories | 13.218 M | 13.063 M | 14.486 M | 14.507 M | 16.131 M | 18.752 M | 17.877 M | 22.988 M | |
| Other Current Assets | 8.598 M | 8.297 M | 6.764 M | 3.977 M | 3.845 M | 3.505 M | 3.794 M | 3.793 M | |
| Short Term Investments | 8.598 M | 8.297 M | 6.764 M | 3.977 M | 3.845 M | 3.505 M | 3.794 M | 3.793 M | |
| Total Receivables | 10.472 M | 8.680 M | 9.729 M | 12.943 M | 12.866 M | 16.096 M | 16.994 M | 13.473 M | |
| Current Cash | 87.606 M | 81.704 M | 81.218 M | 60.247 M | 93.328 M | 78.595 M | 83.125 M | 61.575 M | |
| Total Non-current Assets | 64.369 M | 64.713 M | 63.834 M | 62.623 M | 62.709 M | 60.296 M | 58.579 M | 52.921 M | |
| Property Plant Equipment | 9.390 M | 10.492 M | 10.174 M | 10.425 M | 11.139 M | 10.843 M | 10.729 M | 8.964 M | |
| Other Assets | 15.616 M | 15.215 M | 15.047 M | 14.136 M | 13.860 M | 12.738 M | 11.477 M | 8.296 M | |
| Intangible Assets | 20.799 M | 20.442 M | 20.048 M | 19.496 M | 19.125 M | 18.123 M | 17.412 M | 16.699 M | |
| Goodwill | 18.262 M | 18.262 M | 18.262 M | 18.262 M | 18.262 M | 18.262 M | 18.262 M | 18.262 M | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 184.263 M | 176.457 M | 176.031 M | 154.297 M | 188.879 M | 177.244 M | 180.369 M | 154.750 M | |
| Total liabilities | 93.413 M | 101.369 M | 117.450 M | 112.173 M | 116.978 M | 115.271 M | 126.599 M | 122.027 M | |
| Total current liabilities | 33.783 M | 31.682 M | 37.055 M | 33.223 M | 37.390 M | 35.523 M | 35.345 M | 33.193 M | |
| Accounts Payable | 13.372 M | 8.172 M | 10.628 M | 8.683 M | 11.732 M | 11.890 M | 11.776 M | 10.747 M | |
| Other liabilities | 7.153 M | 7.433 M | 8.153 M | 7.171 M | 7.546 M | 8.177 M | 8.958 M | 6.943 M | |
| Current long term debt | 3.593 M | 3.597 M | 3.629 M | 3.583 M | 3.716 M | 3.589 M | 3.448 M | 3.372 M | |
| Long term debt | 52.352 M | 62.129 M | 72.155 M | 71.692 M | 71.955 M | 71.484 M | 82.258 M | 81.816 M | |
| Other liabilities | 7.153 M | 7.433 M | 8.153 M | 7.171 M | 7.546 M | 8.177 M | 8.958 M | 6.943 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 90.850 M | 75.088 M | 58.581 M | 42.124 M | 71.901 M | 61.973 M | 53.770 M | 32.723 M | |
| Common stock | 37.612 M | 37.901 M | 38.010 M | 38.326 M | 40.640 M | 48.975 M | 49.797 M | 49.188 M | |
| Retained earnings | -130.001 M | -147.873 M | -166.748 M | -185.550 M | -206.353 M | -219.269 M | -230.071 M | -253.555 M |